Peter Borchmann (University of Cologne) describes the HD21 trial outcomes: the novel BrECADD chemotherapy regimen significantly improves progression-free survival for patients with advanced-stage classical Hodgkin lymphoma, compared to the traditional BEACOPP regimen.
- Ай бұрын
Advanced Hodgkin lymphoma, insights from the GHSG HD21 trial
- Рет қаралды 65
Пікірлер